Current pharmacotherapy options for osteomyelitis: Convergences, divergences and lessons to be drawn

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 6, 2013, Pages 723-734

  Senneville, Eric ^a   Nguyen, Sophie ^a  

^a Gustave Dron Hospital   (France)

Author keywords

Antibiotic treatment; Bacterial resistance; Bone biopsy; Osteomyelitis

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFTAROLINE; CEFTOBIPROLE; CEPHALOSPORIN; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; DOXYCYCLINE; ERTAPENEM; FOSFOMYCIN; FUSIDIC ACID; GENTAMICIN; ISOPENICILLIN N; LEVOFLOXACIN; LINEZOLID; MACROLIDE; METRONIDAZOLE; MOXIFLOXACIN; OXACILLIN; PENICILLIN DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BACTEREMIA; BACTERICIDAL ACTIVITY; BIOFILM; BONE MARROW SUPPRESSION; CHRONIC OSTEOMYELITIS; COMBINATION CHEMOTHERAPY; DIABETIC FOOT; DIABETIC FOOT OSTEOMYELITIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CLEARANCE; DRUG DIFFUSION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG MONITORING; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG SPECIFICITY; ENTEROCOCCUS; GRAM POSITIVE BACTERIUM; HEMODIALYSIS; HUMAN; KIDNEY DYSFUNCTION; LACTIC ACIDOSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OPTIC NERVE DISEASE; ORTHOPEDIC SURGERY; OSTEOMYELITIS; OTOTOXICITY; PERIPHERAL NEUROPATHY; PERIPROSTHETIC JOINT INFECTION; PNEUMONIA; REVIEW; SEROTONIN SYNDROME; SINGLE DRUG DOSE; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; ADULT; ANIMALS; ANTI-BACTERIAL AGENTS; CHRONIC DISEASE; DIABETIC FOOT; DRUG DESIGN; HUMANS; OSTEOMYELITIS;

EID: 84875197485     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.780596     Document Type: Review

References (100)

1. Lew DP, Waldvogel FA. Osteomyelitis. Lancet 2004;364:369-79
2. Cierny G, Mader JT, Pennick JJ. A clinical staging system for adult osteomyelitis. Contemp Orthop 1985;10:17-37
3. Spellberg B, Lipsky BA. Systemic antibiotic therapy for chronic osteomyelitis in adults. Clin Infect Dis 2012;54:393-407
4. Salvana J, Rodner C, Browner BD, et al. Chronic osteomyelitis: Results obtained by an integrated team approach to management. Conn Med 2005;69:195-202
5. Peyrani P, Allen M, Seligson D, et al. Clinical outcomes of -steomyelitis patients infected with methicillin-resistant Staphylococcus aureus USA-300 strains. Am J Orthop (Belle Mead NJ) 2012;41:117-22
6. Antibiotic resistance surveillance in Europe 2010. Annual report of the European Antibiotic Resistance Surveillance Network (EARS-Net) Surveillance reports-17 Nov 2011. Available from: Http://www.ecdc.europa. eu
7. Canton R, Akova M, Carmeli Y, et al. European Network on Carbapenemases. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 2012;18:413-31
8. Senneville E, Melliez H, Beltrand E, et al. Culture of percutaneous bone biopsy specimens for diagnosis of diabetic foot osteomyelitis: Concordance with ulcer swab cultures. Clin Infect Dis 2006;42:57-62
9. Zuluaga AF, Galvis W, Jaimes F, Vespa O. Lack of microbiological concordance between bone and non-bone specimens in chronic osteomyelitis: An observational study. BMC Infect Dis 2002;2:8
10. Marschall J, Bhavan KP, Olsen MA, et al. The impact of prebiopsy antibiotics on pathogen recovery in hematogenous vertebral osteomyelitis. Clin Infect Dis 2011;52:867-72
11. Landersdorfer CB, Bulitta JB, Kinzig M, et al. Penetration of antibacterials into bone: Pharmacokinetic, pharmacodynamic and bioanalytical considerations. Clin Pharmacokinet 2009;48:89-124
12. Pea F. Penetration of antibacterials into bone: What do we really need to know for optimal prophylaxis and treatment of bone and joint infections? Clin Pharmacokinet 2009;48:125-7
13. Widmer AF, Frei R, Rajacic Z, Zimmerli W. Correlation between in vivo and in vitro efficacy of antibiotic agents against foreign body infections. J Infect Dis 1990;162:96-102
14. Widmer AF, Wiestner A, Frei R, Zimmerli W. Killing of nongrowing and adherent Escherichia coli determines drug efficacy in device-related infections. Antimicrob Agents Chemother 1991;35:741-6
15. Murillo O, Domenech A, Garcia A, et al. Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2006;50:4011-17
16. Mascio CT, Alder JD, Silverman JA. Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob Agents Chemother 2007;51:4255-60
17. Sedghizadeh PP, Kumar SK, Gorur A, et al. Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy. J Am Dent Assoc 2009;140:1259-65
18. Patel R. Biofilms and Antibiotic resistance. Clin Orthop Relat Res 2005;437:41-7
19. Norden CW, Bryant R, Palmer D, et al. Chronic osteomyelitis caused by Staphylococcus aureus: Controlled clinical trial of nafcillin therapy and nafcillin-rifampin therapy. South Med J 1986;79:947-51
20. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66:82-98
21. Lodise TP, Patel N, Lomaestro BM, et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009;49:507-14
22. Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: Systematic review and meta-analysis. Antimicrob Agents Chemother 2009;53:4069-79
23. LeFrock J, Ristuccia A. Teicoplanin in the treatment of bone and joint infections: An open study. J Infect Chemother 1999;5:32-9
24. Lemaire X, Loiez C, Valette M, et al. Comparison of vancomycin and teicoplanin trough serum levels in patients with infected orthopedic devices: New data for old therapies. J Infect Chemother 2011;17:370-4
25. Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003;47:2538-44
26. Nannini E, Murray BE, Arias CA. Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus. Curr Opin Pharmacol 2010;10:516-21
27. Traunmuller F, Schintler MV, Metzler J, et al. Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. J Antimicrob Chemother 2010;65:1252-7
28. Lefebvre M, Jacqueline C, Amador G, et al. Efficacy of daptomycin combined with rifampicin for the treatment of experimental methicillin-resistant Staphylococcus aureus (MRSA) acute osteomyelitis. Int J Antimicrob Agents 2010;36:542-4
29. Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin:a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 2005;55:283-8
30. Garrigos C, Murillo O, Euba G, et al. Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2010;54:5251-6
31. Parra-Ruiz J, Bravo-Molina A, Pena-Monje A, Hernandez-Quero J. Activity of linezolid and high-dose daptomycin, alone or in combination, in an in vitro model of Staphylococcus aureus biofilm. J Antimicrob Chemother 2012;2682-5
32. Burkhardt O, Kielstein JT. A simplified three-times weekly daptomycine dosing regimen for chronic hemodialysis patients. Expert Rev Anti Infect Ther 2010;8:11-14
33. Kielstein JT, Eugbers C, Bode-Boeger SM, et al. Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis-a pharmacokinetic study. Nephrol Dial Transplant 2010;25:1537-41
34. Holtom PD, Zalavras CG, Lamp KC, et al. Clinical experience with daptomycin treatment of foot or ankle osteomyelitis: A preliminary study. Clin Orthop Relat Res 2007;461:35-9
35. Lamp KC, Friedrich LV, Mendez-Vigo L, Russo R. Clinical experience with daptomycin for the treatment of patients with osteomyelitis. Am J Med 2007;120(10 Suppl 1):S13-20
36. Byren I, Rege S, Campanaro E, et al. Two-stage revision arthroplasty with prosthetic devices undergoing of patients with osteomyelitis associated standard-of-care therapy for management and efficacy of daptomycin versus. Antimicrob Agents Chemother 2012;56:5626-32
37. Gallagher JC, Huntington JA, Culshaw D, et al. Daptomycin therapy for osteomyelitis: A retrospective study. BMC Infect Dis 2012;12:133
38. Moenster RP, Linneman TW, Finnegan PM, McDonald Jr. Daptomycin compared to vancomycin for the treatment of osteomyelitis: A single-center, retrospective cohort study. Clin Ther 2012;34:1521-7
39. Pillai KS, Wennersten CB, Venkataraman L, et al. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aurous. Clin Infect Dis 2009;49:1169-74
40. Marty FM, Yeh WW, Wennersten CB, et al. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol 2006;44:595-7
41. Berti AD, Wergin JE, Girdaukas GG, et al. Altering the proclivity towards daptomycin resistance in methicillin-resistant Staphylococcus aureus using combinations with other antibiotics. Antimicrob Agents Chemother 2012;56:5046-53
42. Garrigos C, Murillo O, Lora-Tamayo J, et al. Fosfomycin-daptomycin and other fosfomycin combinations as alternative therapies in experimental foreign-body infection by methicillin-resistant staphylococcus aurous. Antimicrob Agents Chemother 2013;57:606-10
43. Parra-Ruiz J, Pena-Monje A, Tomas-Jimenez C, et al. Efficacy and safety of high dose (‡ 8 mg/kg/day) daptomycin. Enferm Infecc Microbiol Clin 2011;29:425-7
44. Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: A retrospective survey. Clin Infect Dis 2006;43:180-7
45. Wu VC, Wang YT, Wang CY, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis 2006;42:66-72
46. Palenzuela L, Hahn NM, Nelson RP Jr, et al. Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis? Clin Infect Dis 2005;40:113-16
47. Senneville E, Legout L, Valette M, et al. Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: A retrospective study. Clin Ther 2006;28:1155-63
48. Chesi G, Colli A, Mestres CA, et al. Multiresistant-MRSA tricuspid valve infective endocarditis with ancient osteomyelitis locus. BMC Infect Dis 2006;26:124
49. Legout L, Valette M, Dezeque H, et al. Tolerability of prolonged linezolid therapy in bone and joint infection: Protective effect of rifampicin on the occurrence of anaemia? J Antimicrob Chemother 2010;65:2224-30
50. Gandelman K, Zhu T, Fahmi OA, et al. Unexpected effect of rifampin on the PK of linezolid: In silico and in vitro approaches to explain its mechanism. J Clin Pharmacol 2011;51:229-36
51. Pea F, Viale P, Cojutti P, et al. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother 2012;67:2034-42
52. Saginur R, Stdenis M, Ferris W, et al. Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections. Antimicrob Agents Chemother 2006;50:55-61
53. Yamaoka T. The bactericidal effects of anti-MRSA agents with rifampicin and sulfamethoxazole-trimethoprim against intracellular phagocytized MRSA. J Infect Chemother 2007;13:141-6
54. Van der Auwera P, Klastersky J, Thys JP, et al. Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections. Antimicrob Agents Chemother 1985;28:467-72
55. Norden CW, Bryant R, Palmer D, et al. Chronic osteomyelitis caused by Staphylococcus aureus: Controlled clinical trial of nafcillin therapy and nafcillin-rifampin therapy. South Med J 1986;79:947-51
56. Wehrli W. Rifampin: Mechanisms of action and resistance. Rev Infect Dis 1983;5(Suppl 1):407-11
57. Zeller V, Dzeing-Ella A, Kitzis MD, et al. Continuous clindamycin infusion, an innovative approach to treating bone and joint infections. Antimicrob Agents Chemother 2010;54:88-92
58. Nijland HM, Ruslami R, Suroto AJ, et al. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis 2007;45:1001-7
59. Zimmerli W, Widmer A, Blatter M, et al. Role of rifampin for treatment of orthopaedic implant-related staphylococcal infections. JAMA 1998;279:1537-41
60. El Helou OC, Berbari EF, Lahr BD. Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention. Eur J Clin Microbiol Infect Dis 2010;29:9617
61. Senneville E, Joulie D, Legout L, et al. Outcome and predictors of treatment failure in total hip/knee prosthetic joint infections due to Staphylococcus aureus. Clin Infect Dis 2011;53:334-40
62. Lora-Tamayo J, Murillo O, Iribarren JA, et al. "A Large multicenter study of methicillin-susceptible and methicillin-resistant staphylococcus aureus prosthetic joint infections managed with implant retention". Clin Infect Dis 2013;56(2):182-94
63. Olson ME, Slater SR, Rupp ME, Fey PD. Rifampicin enhances activity of daptomycin and vancomycin against both a polysaccharide intercellular adhesin (PIA)- dependent and -independent Staphylococcus epidermidis biofilm. J Antimicrob Chemother 2010;65:2164-71
64. Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012;54:1699-709
65. Kandemir O, Oztuna V, Colak M, et al. Comparison of the efficacy of tigecycline and teicoplanin in an experimental methicillin-resistant Staphylococcus aureus osteomyelitis model. J Chemother 2008;20:53-7
66. Yin LY, Calhoun JH, Thomas TS, Wirtz ED. Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: Studies with a rabbit model. J Antimicrob Chemother 2009;63:357-60
67. Twilla JD, Gelfand MS, Cleveland KO, Usery JB. Telavancin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis. J Antimicrob Chemother 2011;66:2675-7
68. Telavancin (Vibativ) Prescribing Information. Theravance, Inc./Astellas Pharma US, Inc, South San Francisco, CA/Deerfield, IL; 2009
69. Kollef MH. New Antibiotic agents for methicillin-resistant Staphylococcus aureus. Crit Care Resusc 2009;11:282-6
70. Jacqueline C, Amador G, Caillon J, et al. Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis. J Antimicrob Chemother 2010;65:1749-52
71. Atkins B, Gottlieb T. Fusidic acid in bone and joint infections. Int J Antimicrob Agents 1999;12(Suppl 2):S79-93
72. Ruparelia N, Atkins BL, Hemingway J, et al. Pristinamycin as adjunctive therapy in the management of Gram-positive multi-drug resistant organism (MDRO) osteoarticular infection. J Infect 2008;57:191-7
73. Popovic M, Steinort D, Pillai S, Joukhadar C. Fosfomycin: An old, new friend? Eur J Clin Microbiol Infect Dis 2009;29:127-42
74. Aligholi M, Emaneini M, Taherikalani M, et al. Time-kill study and synergistic activity of cell-wall inhibitor antibiotics in combination with gentamicin against Enterococcus faecalis and Enterococcus faecium. Acta Microbiol Immunol Hung 2011;58:219-26
75. Euba G, et al. Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis. Antimicrob Agents Chemother 2009;53(6):2672-6
76. Berbari EF, Steckelberg JM, Osmon DR. Osteomyelitis. In: Mandell GL, editor. Principles and practice of infectious diseases. Elsevier, Philadelphia; 2005. p. 1322
77. Carvalho VC, Oliveira PR, Dal-Paz K, et al. Gram-negative osteomyelitis: Clinical and microbiological profile. Braz J Infect Dis 2012;16:63-7
78. Galanakis N, Giamarellou H, Moussas T, Dounis E. Chronic osteomyelitis caused by multi-resistant Gram-negative bacteria: Evaluation of treatment with newer quinolones after prolonged follow-up. J Antimicrob Chemother 1997;39:241-6
79. Tice AD, Hoaglund PA, Shoultz DA. Risk factors and treatment outcomes in osteomyelitis. J Antimicrob Chemother 2003;51:1261-8
80. Barberan J, Gomis M, Sanchez B, et al. Cefepime in the treatment of osteomyelitis caused by Gram negative bacilli. Rev Esp Quimioter 2000;13:366-73
81. Jauregui L, Matzke D, Scott M, et al. Cefepime as treatment for osteomyelitis and other severe bacterial infections. J Antimicrob Chemother 1993;32(Suppl B):141-9
82. Widmer AF, Wiestner A, Frei R, Zimmerli W. Killing of nongrowing and adherent Escherichia coli determines drug efficacy in device-related infections. Antimicrob Agents Chemother 1991;35:741-6
83. Legout L, Senneville E, Stern R, et al. Treatment of bone and joint infections caused by Gram-negative bacilli with a cefepime-fluoroquinolone combination. Clin Microbiol Infect 2006;12:1030-3
84. Tice AD. Ertapenem: A new opportunity for outpatient parenteral Antibiotic therapy. J Antimicrob Chemother 2004;53(Suppl 2):83-6
85. Goswami ND, Johnson MD, Chu VH. Ertapenem for treatment of osteomyelitis: A case series. BMC Res Notes 2011;2:478
86. Ferry T, Senechal A, Gagnieu MC, et al. Prolonged subcutaneous high dose (1 g bid) of Ertapenem as salvage therapy in patients with difficult-to-treat bone and joint infection. J Infect 2012;65:579-82
87. Kubin CJ, Ellman TM, Phadke V, et al. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. J Infect 2012;65:80-7
88. Balaji V, Jeremiah SS, Baliga PR. Polymyxins: Antimicrobial susceptibility concerns and therapeutic options. Indian J Med Microbiol 2011;29:230-42
89. Han IH, Choi BK, Nam KH, Kim SY. Bacteroides fragilis vertebral osteomyelitis complicated by percutaneous epidural adhesiolysis: A case report. Spine (Phila Pa 1976) 2013; [Epub ahead of print]
90. Walter G, Kemmerer M, Kappler C, Hoffmann R. Treatment Algorithms for Chronic Osteomyelitis. Dtsch Arztebl Int 2012;109:257-64
91. Fraimow HS. Systemic Antibiotic therapy in osteomyelitis. Semin Plast Surg 2009;23:90-9
92. Lipsky BA, Berendt AR, Cornia PB, et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2012;54:e132-73
93. Senneville E, Lombart A, Beltrand E, et al. Outcome of diabetic foot osteomyelitis treated nonsurgically: A retrospective cohort study. Diabetes Care 2008;31:637-42
94. Venkatesan P, Lawn S, Macfarlane RM, et al. Conservative management of osteomyelitis in the feet of diabetic patients. Diabet Med 1997;14:487-90
95. Senneville E, Yazdanpanah Y, Cazaubiel M, et al. Rifampicin-ofloxacin oral regimen for the treatment of mild to moderate diabetic foot osteomyelitis. J Antimicrob Chemother 2001;48:927-30
96. Pulcini C, Couadau T, Bernard E, et al. Adverse effects of parenteral Antibiotic therapy for chronic bone infections. Eur J Clin Microbiol Infect Dis 2008;27:1227-32
97. Barbot A, Venisse N, Rayeh F, et al. Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors. Intensive Care Med 2003;29:1528-34
98. Conterno LO, da Silva Filho CR. Antibiotics for treating chronic osteomyelitis in adults. Cochrane Database Syst Res 2009;8:CD004439
99. Norden CW, Shinners E, Niederriter K. Clindamycin treatment of experimental chronic osteomyelitis due to Staphylococcus aureus. J Infect Dis 1986;153:956-9
100. Wu M, von Eiff C, Al Laham N, Tsuji BT. Vancomycin and daptomycin pharmacodynamics differ against a site-directed Staphylococcus epidermidis mutant displaying the small-colony-variant phenotype. Antimicrob Agents Chemother 2009;53:3992-5